¹û¶³Ó°Ôº

XClose

¹û¶³Ó°Ôº Therapeutic Innovation Networks

Home
Menu

Therapeutic Design & Development (Small Molecules)

Highlighting important considerations during the "Therapeutic Design & Development" stage of the Small Molecules translational pathway.

Ìý

small molecules roadmap

light bulb
IDEA:

Target Product Profile (TPP) – captures the ‘benefit’ of the proposed therapeutic and key considerations in the strategic development of the product (incl. technical, scientific and medical information required to satisfy key stakeholders (regulators and funders)).

It's commonÌýfor a team to not know the answers to all questions at the start of the project, however this will be refined and developed as the project progresses.Ìý

¹û¶³Ó°Ôº Support:

The ¹û¶³Ó°ÔºÌýTranslational Research Office Drug Discovery Group (TRO DDG) have extensive knowledge and experience of the Small moleculesÌýlandscape, and can provide advice on early considerations such as intended use and drug description etc, to guide development, as well as longer-term considerations for adoptionÌýi.e. help you produce and develop your TPP.Ìý

Contact the ¹û¶³Ó°Ôº TRO Drug Discovery Group

stethoscope
UNMET CLINICAL NEED:

As part of the TPP, comprehensively research and define the potential for benefit of the proposed therapeutic over current ‘standard of care’.Ìý

¹û¶³Ó°Ôº Support:Ìý

Small Molecule Therapeutic Innovation Network is a network of those focused on small molecule drug discovery at ¹û¶³Ó°Ôº.Ìý¹û¶³Ó°Ôº and partner NHS Trusts are globally leading innovators in the discovery, design, development, screening, clinical delivery of small molecule drugs.

The Small Molecule TIN committee expertise in small molecule research which spans multiple therapeutic areas, working across disciplinary boundaries and with our NHS partners to bring novel candidates to the market, and breathe new life into existing candidates.

Learn more about the Small MoleculesÌýTIN

Padlock
INTELLECTUAL PROPERTY:

Engage with Business expertsÌýto ascertain if you have a novel invention, ensure freedom to operate and to protect foreground/arising intellectual property.

¹û¶³Ó°Ôº Support:

If you believe you haveÌýan innovative, patentable technology, it’s important you Ìýbefore any form of public domain disclosure.

¹û¶³Ó°ÔºB are experts that provide confidential support for researchers at ¹û¶³Ó°Ôº, to understand the value of your invention and the best approach to protecting your intellectual property (IP),Ìýadvising on strategies to commercialise your researchÌýsuch as through forming a spin out company or licensing to a third party.Ìý

All researchers with potentially commercialisable research results should fill out a confidential Invention Disclosure Form (IDF) and submit it to their ¹û¶³Ó°ÔºB Business Manager:

people talking
PATIENT & PUBLIC INVOLVEMENT (PPI):

Understanding the patient and clinician needs Ìý- Does your TPP meet all of the essential requirements expressed by frontline clinical care providers, patient and public contributors (PPI)?

Important PPI actions:

  • Research is carried out ‘with’ members of the public – Advisory members of a project steering group
  • Early PPI engagement will help raise awareness of the therapeutic during development and potentially facilitate patient recruitment for subsequent clinical evaluation, possibly even financial investment
  • Timely identification of future needs or opportuniti

Further information on PPI can be found via INVOLVE:

¹û¶³Ó°Ôº Support:Ìý

The ¹û¶³Ó°Ôº Translational Research Office (TRO) can help with the timely identification of future needs or opportunities for diversifying, as well as advising on appropriateÌýpatient groups and charities to consider.Ìý

Contact the ¹û¶³Ó°Ôº Translational Research Office

money hands
FINANCE:

The development of small molecule compound to clinical level has significant costs that must be met. Additionally,ÌýVAT needs to be added for manufacturing and/or services not resulting in a medicinal product.

¹û¶³Ó°Ôº Support:

The ¹û¶³Ó°Ôº Translational Research Office supports ¹û¶³Ó°Ôº researchers in attracting and managing public, commercial, investor and philanthropic funding for the development of small molecules and pre-clinical studies. These projects are then either spun out into a company or partnered with a pharmaceutical company, to help progress the project to clinical studies.

Contact the ¹û¶³Ó°Ôº Translational Research Office (TRO)

Clinical studies need to be appropriately costed in partnership with the Joint Research Office (JRO) or appropriate CTU.

Contact the Joint Research Office (JRO)